AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
232.08
+7.39 (3.29%)
At close: Feb 27, 2026, 4:00 PM EST
231.13
-0.95 (-0.41%)
After-hours: Feb 27, 2026, 7:59 PM EST
AbbVie Revenue
In the year 2025, AbbVie had annual revenue of $61.16B with 8.57% growth. AbbVie had revenue of $16.62B in the quarter ending December 31, 2025, with 10.04% growth.
Revenue (ttm)
$61.16B
Revenue Growth
+8.57%
P/S Ratio
6.71
Revenue / Employee
$1,072,982
Employees
57,000
Market Cap
410.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.16B | 4.83B | 8.57% |
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Eli Lilly and Company | 65.18B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
ABBV News
- 1 day ago - Best Dividend Aristocrats For March 2026 - Seeking Alpha
- 2 days ago - Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie - Seeking Alpha
- 4 days ago - AbbVie to Present at the TD Cowen 46th Annual Health Care Conference - PRNewsWire
- 5 days ago - AbbVie to invest $380 million to expand US manufacturing in Illinois - Reuters
- 5 days ago - AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States - PRNewsWire
- 8 days ago - U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) - PRNewsWire
- 9 days ago - AbbVie Declares Quarterly Dividend - PRNewsWire
- 11 days ago - AbbVie: Dominating Immunology While Building Oncology Upside - Seeking Alpha